Form 4: Agios Pharmaceuticals Director Maykin Ho Reports Significant Equity Grants and RSU Conversion

Agios Pharmaceuticals, Inc. Director Maykin Ho reported the acquisition of 2,816 restricted stock units and 15,768 stock options, alongside the conversion of 2,120 restricted stock units into common stock.

Summary

• Maykin Ho, a Director at Agios Pharmaceuticals, Inc. (AGIO), reported several equity transactions.
• On June 18, 2025, Ms. Ho was granted 2,816 restricted stock units (RSUs) which will vest in full on June 18, 2026.
• Also on June 18, 2025, Ms. Ho was granted 15,768 stock options with an exercise price of $35.5, which will vest 100% on June 18, 2026, and expire on June 18, 2035.
• On June 20, 2025, 2,120 restricted stock units, granted on June 20, 2024, vested and were converted into common stock.
• Following these transactions, Ms. Ho directly beneficially owns 17,032 shares of common stock, 2,816 restricted stock units, and 15,768 stock options.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it's a routine insider transaction report, the acquisition of new equity awards and the conversion of RSUs into common stock by a director generally signal continued alignment of interests with the company's long-term performance and confidence in its future.

Positives

• The grant of 2,816 restricted stock units and 15,768 stock options aligns the director's interests with long-term shareholder value, as these awards vest over time.
• The conversion of 2,120 restricted stock units into common stock indicates a successful vesting event for previously granted awards, increasing the director's direct share ownership.

Future Outlook

The vesting schedules for the newly granted restricted stock units and stock options indicate that these equity awards will fully vest on June 18, 2026, aligning the director's future compensation with the company's performance over the coming year.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in the biotechnology and pharmaceutical industry, where stock options and restricted stock units are commonly used to incentivize long-term commitment and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The increase in director's beneficial ownership through equity grants and RSU conversion aligns the director's financial interests with shareholders, potentially fostering better long-term decision-making.

Next Steps

• Delivery of vested shares to the reporting person within three business days after June 18, 2026, for the newly granted RSUs and options.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Grant, Director Compensation, Beneficial Ownership